New Once-Daily pill for Wilson's disease tested for patient preference
NCT ID NCT07010575
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether people with Wilson's disease prefer a new once-daily version of the drug trientine over their usual treatment, which is taken multiple times a day. Ten adults on stable standard care tried the new formulation and reported their satisfaction and convenience. The goal was to see if a simpler dosing schedule could improve treatment experience.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILSON'S DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
VCTC
Hartshorne, Derbyshire, DE11 7AQ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden heart risks in Wilson's disease: a new scan could spot them early
- Can a global patient registry unlock the mysteries of Wilson's disease?
- Can a single infusion rewrite the genetic code behind wilson disease?
- Gene therapy could free Wilson's patients from daily pills
- New Once-Daily drug could simplify Wilson's disease treatment
- New blood tests could simplify Wilson's disease monitoring